CNQ · BETR.CN
BetterLife Pharma Inc.
CA$0.25+CA$0.01 (+4.17%)
BetterLife Pharma Inc.’s quoted price sits in the upper half of its reported 52-week range, 45.65% below the high.
Loading market information…
OTC · CUBT · USD
Stock price, earnings
Quote as of Oct 29, 2026, 05:56 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Curative Biotechnology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 58.32% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Curative Biotechnology, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Curative Biotechnology, Inc. is an emerging biomedical firm primarily focused on developing pharmaceutical products. Its research and development efforts are concentrated on a diverse pipeline targeting critical therapeutic areas, including infectious diseases, cancer, and vision-impairing degenerative eye conditions. Among its key pipeline assets is IMT504, an innovative immunotherapy designed for rabies treatment and as a vaccine enhancer. Another prominent candidate is CUBT906, a fully humanized CD56 monoclonal antibody that delivers a pyrrolobenzodiazepine dimer directly to tumor cells, aiming to eradicate them by halting their growth and spread. Additionally, the company is advancing a reformulated Metformin for the management of degenerative eye disorders. Curative Biotechnology has entered into a licensing and co-development partnership with Mid-Atlantic BioTherapeutics, Inc. to further advance IMT504, specifically for addressing advanced rabies and as a component of a COVID-19 vaccine. Previously known as Connectyx Technologies Holdings Group, Inc., the company adopted its current name, Curative Biotechnology, Inc., in November 2020. Established in 1995, the company maintains its headquarters in Boca Raton, Florida.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 11:08 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CA$0.25+CA$0.01 (+4.17%)
BetterLife Pharma Inc.’s quoted price sits in the upper half of its reported 52-week range, 45.65% below the high.
$0.01+$0.00 (+6.67%)
ProText Mobility, Inc.’s quoted price sits in the lower half of its reported 52-week range, 42.86% below the high.
$0.10$0.00 (0.0%)
Quantum Genomics S.A.: Healthcare · Biotechnology.
CA$0.04CA$0.00 (0.0%)
Glow Lifetech Corp.’s quoted price sits in the lower half of its reported 52-week range, 38.46% below the high.
$0.10$0.00 (0.0%)
Chimeric Therapeutics Limited’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.09$0.00 (0.0%)
BioVaxys Technology Corp.’s quoted price sits in the lower half of its reported 52-week range, 56.73% below the high.
$0.14$0.00 (0.0%)
Mosaic ImmunoEngineering Inc.’s quoted price sits in the lower half of its reported 52-week range, 84.61% below the high.
£0.00-£0.00 (-0.53%)
Futura Medical plc’s quoted price sits in the lower half of its reported 52-week range, 93.29% below the high.
